News

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen…

AbstractAmyloidosis, characterized by the deposition of abnormal protein fibrils in organs, is classified as systemic or localized. Amyloid light chain (AL)-type…

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen…

BRAZIL - Brazil’s health regulatory agency ANVISA granted marketing authorization for acoramidis, branded as Beyonttra, for treating transthyretin amyloidosis with…

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this…

Key TakeawaysClaims-based analysis showed 64% of patients received ATTR-CM diagnosis ≥6 months after incident HF, with median delays approaching 1.4 years and…

Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR–CM) is an increasingly recognised cause of heart failure in older adults, but real–world data in patients…

AbstractBackgroundTransthyretin amyloidosis (ATTR) is a degenerative disease affecting the heart and other organs. Transthyretin (TTR) aggregation is a driver of…

AbstractCardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by…